Enzon regains compliance with Nasdaq


Enzon Pharmaceuticals on June 25 received a letter from the Listing Qualifications staff of The NASDAQ Stock Market indicating that the Nasdaq Staff has determined that for the last 10 consecutive business days, from June 10 to June 23, the closing bid price of the company’s common stock has been at $1.00 per share or greater and, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550a2.

View Comments (0)